These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 27839909)

  • 1. Histologic Subtype in Core Lung Biopsies of Early-Stage Lung Adenocarcinoma is a Prognostic Factor for Treatment Response and Failure Patterns After Stereotactic Body Radiation Therapy.
    Leeman JE; Rimner A; Montecalvo J; Hsu M; Zhang Z; von Reibnitz D; Panchoo K; Yorke E; Adusumilli PS; Travis W; Wu AJ
    Int J Radiat Oncol Biol Phys; 2017 Jan; 97(1):138-145. PubMed ID: 27839909
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Micropapillary and/or Solid Histologic Subtype Based on Pre-Treatment Biopsy Predicts Local Recurrence After Thermal Ablation of Lung Adenocarcinoma.
    Gao S; Stein S; Petre EN; Shady W; Durack JC; Ridge C; Adusumilli P; Rekhtman N; Solomon SB; Ziv E
    Cardiovasc Intervent Radiol; 2018 Feb; 41(2):253-259. PubMed ID: 28770314
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic significance and adjuvant chemotherapy survival benefits of a solid or micropapillary pattern in patients with resected stage IB lung adenocarcinoma.
    Qian F; Yang W; Wang R; Xu J; Wang S; Zhang Y; Jin B; Yu K; Han B
    J Thorac Cardiovasc Surg; 2018 Mar; 155(3):1227-1235.e2. PubMed ID: 29223834
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Histology significantly affects recurrence and survival following SBRT for early stage non-small cell lung cancer.
    Baine MJ; Verma V; Schonewolf CA; Lin C; Simone CB
    Lung Cancer; 2018 Apr; 118():20-26. PubMed ID: 29571997
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Histology of non-small cell lung cancer predicts the response to stereotactic body radiotherapy.
    Hörner-Rieber J; Bernhardt D; Dern J; König L; Adeberg S; Paul A; Heussel CP; Kappes J; Hoffmann H; Herth FJP; Debus J; Warth A; Rieken S
    Radiother Oncol; 2017 Nov; 125(2):317-324. PubMed ID: 28919006
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Solid predominant histologic subtype and early recurrence predict poor postrecurrence survival in patients with stage I lung adenocarcinoma.
    Luo J; Wang R; Han B; Zhang J; Zhao H; Fang W; Luo Q; Yang J; Yang Y; Zhu L; Chen T; Cheng X; Huang Q; Wang Y; Zheng J; Chen H
    Oncotarget; 2017 Jan; 8(4):7050-7058. PubMed ID: 27732964
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictors of Nodal and Metastatic Failure in Early Stage Non-small-cell Lung Cancer After Stereotactic Body Radiation Therapy.
    Cerra-Franco A; Liu S; Azar M; Shiue K; Freije S; Hinton J; Deig CR; Edwards D; Estabrook NC; Ellsworth SG; Huang K; Diab K; Langer MP; Zellars R; Kong FM; Wan J; Lautenschlaeger T
    Clin Lung Cancer; 2019 May; 20(3):186-193.e3. PubMed ID: 30711394
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Location Matters: Stage I Non-Small-cell Carcinomas of the Lower Lobes Treated With Stereotactic Body Radiation Therapy Are Associated With Poor Outcomes.
    Shaverdian N; Veruttipong D; Wang J; Kupelian P; Steinberg M; Lee P
    Clin Lung Cancer; 2017 Mar; 18(2):e137-e142. PubMed ID: 27908620
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stereotactic body radiation therapy versus conventional radiation therapy in patients with early stage non-small cell lung cancer: an updated retrospective study on local failure and survival rates.
    Jeppesen SS; Schytte T; Jensen HR; Brink C; Hansen O
    Acta Oncol; 2013 Oct; 52(7):1552-8. PubMed ID: 23902274
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of pretreatment tumor growth rate on outcome of early-stage lung cancer treated with stereotactic body radiation therapy.
    Atallah S; Cho BC; Allibhai Z; Taremi M; Giuliani M; Le LW; Brade A; Sun A; Bezjak A; Hope AJ
    Int J Radiat Oncol Biol Phys; 2014 Jul; 89(3):532-8. PubMed ID: 24929163
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlation of mutation status and survival with predominant histologic subtype according to the new IASLC/ATS/ERS lung adenocarcinoma classification in stage III (N2) patients.
    Russell PA; Barnett SA; Walkiewicz M; Wainer Z; Conron M; Wright GM; Gooi J; Knight S; Wynne R; Liew D; John T
    J Thorac Oncol; 2013 Apr; 8(4):461-8. PubMed ID: 23486266
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lung stereotactic body radiation therapy: regional nodal failure is not predicted by tumor size.
    Marwaha G; Stephans KL; Woody NM; Reddy CA; Videtic GM
    J Thorac Oncol; 2014 Nov; 9(11):1693-7. PubMed ID: 25185531
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Retrospective Long-term Follow-up Study of Stereotactic Body Radiation Therapy for Non-Small Cell Lung Cancer From a Single Institution: Incidence of Late Local Recurrence.
    Shintani T; Matsuo Y; Iizuka Y; Mitsuyoshi T; Mizowaki T
    Int J Radiat Oncol Biol Phys; 2018 Apr; 100(5):1228-1236. PubMed ID: 29722662
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of stereotactic body radiation therapy for biopsy-proven versus radiographically diagnosed early-stage non-small lung cancer: a single-institution experience.
    Fischer-Valuck BW; Boggs H; Katz S; Durci M; Acharya S; Rosen LR
    Tumori; 2015; 101(3):287-93. PubMed ID: 25908031
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Micropapillary and solid subtypes of invasive lung adenocarcinoma: clinical predictors of histopathology and outcome.
    Cha MJ; Lee HY; Lee KS; Jeong JY; Han J; Shim YM; Hwang HS
    J Thorac Cardiovasc Surg; 2014 Mar; 147(3):921-928.e2. PubMed ID: 24199757
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stereotactic body radiotherapy with adjuvant systemic therapy for early-stage non-small cell lung carcinoma: A multi-institutional analysis.
    Kann BH; Miccio JA; Stahl JM; Ross R; Verma V; Dosoretz AP; Park HS; Shafman TD; Gross CP; Yu JB; Decker RH
    Radiother Oncol; 2019 Mar; 132():188-196. PubMed ID: 30391106
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stereotactic Body Radiation Therapy for Stage I Non-Small Cell Lung Cancer: A Retrospective, Single-Center Study of 55 Patients.
    Bhandari RP; Stanford JD; Packianathan S; Duggar WN; Kanakamedala MR; Zhang X; Giri SP; Kumar PP; Harrell LM; Mangana SH; Yang C; Vijayakumar S
    Oncology; 2016; 91(4):194-204. PubMed ID: 27427761
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recurrence After Stereotactic Body Radiation Therapy Versus Lobectomy for Non-Small Cell Lung Cancer.
    Sebastian NT; Merritt RE; Abdel-Rasoul M; Wu T; Bazan JG; Xu-Welliver M; Haglund K; D'Souza D; Kneuertz PJ; Williams TM
    Ann Thorac Surg; 2020 Sep; 110(3):998-1005. PubMed ID: 32353436
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Histologic Basis for the Efficacy of SBRT to the lung.
    Woody NM; Stephans KL; Andrews M; Zhuang T; Gopal P; Xia P; Farver CF; Raymond DP; Peacock CD; Cicenia J; Reddy CA; Videtic GM; Abazeed ME
    J Thorac Oncol; 2017 Mar; 12(3):510-519. PubMed ID: 28017592
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Local control for clinical stage I non-small cell lung cancer treated with 5-fraction stereotactic body radiation therapy is not associated with treatment schedule.
    Samson P; Rehman S; Juloori A; DeWees T; Roach M; Bradley J; Videtic GMM; Stephans K; Robinson C
    Pract Radiat Oncol; 2018; 8(6):404-413. PubMed ID: 29907514
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.